Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) CEO Frank D. Lee bought 8,264 shares of the business’s stock in a transaction on Monday, August 12th. The stock was bought at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares of the company’s stock, valued at approximately $1,304,186.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Pacira BioSciences Trading Up 7.1 %
Shares of PCRX stock opened at $13.35 on Friday. The stock has a 50-day simple moving average of $22.59 and a 200 day simple moving average of $26.88. The stock has a market capitalization of $615.84 million, a P/E ratio of 9.34 and a beta of 0.88. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $38.23. The company has a quick ratio of 5.70, a current ratio of 6.82 and a debt-to-equity ratio of 0.67.
Institutional Investors Weigh In On Pacira BioSciences
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Pacira BioSciences by 5.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,973 shares of the company’s stock valued at $741,000 after purchasing an additional 1,186 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Pacira BioSciences in the fourth quarter worth about $783,000. Cornercap Investment Counsel Inc. increased its position in shares of Pacira BioSciences by 14.1% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 35,375 shares of the company’s stock worth $1,194,000 after acquiring an additional 4,368 shares in the last quarter. abrdn plc lifted its position in shares of Pacira BioSciences by 14.3% in the 4th quarter. abrdn plc now owns 448,691 shares of the company’s stock valued at $15,139,000 after acquiring an additional 56,081 shares in the last quarter. Finally, Duality Advisers LP lifted its position in shares of Pacira BioSciences by 4.9% in the 4th quarter. Duality Advisers LP now owns 34,179 shares of the company’s stock valued at $1,153,000 after acquiring an additional 1,591 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Pacira BioSciences
About Pacira BioSciences
Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
Further Reading
- Five stocks we like better than Pacira BioSciences
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Jeff Brown’s Exegesis AI Stock Picks
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.